Poseida Therapeutics, Inc. to Post Q3 2025 Earnings of ($0.49) Per Share, HC Wainwright Forecasts (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX) – Equities research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Poseida Therapeutics in a research note issued on Wednesday, May 22nd. HC Wainwright analyst A. He forecasts that the company will post earnings per share of ($0.49) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Poseida Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Poseida Therapeutics’ Q4 2025 earnings at ($0.51) EPS and FY2028 earnings at $0.26 EPS.

Poseida Therapeutics Stock Up 3.0 %

Shares of PSTX opened at $3.06 on Thursday. Poseida Therapeutics has a one year low of $1.54 and a one year high of $4.27. The company has a 50-day moving average of $2.79 and a two-hundred day moving average of $3.02. The company has a current ratio of 2.56, a quick ratio of 2.56 and a debt-to-equity ratio of 0.69.

Poseida Therapeutics (NASDAQ:PSTX) last announced its earnings results on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 131.95% and a negative return on equity of 97.36%. The firm had revenue of $25.00 million during the quarter, compared to analyst estimates of $12.50 million.

Institutional Trading of Poseida Therapeutics

Hedge funds have recently made changes to their positions in the stock. Silverarc Capital Management LLC raised its position in Poseida Therapeutics by 21.1% during the third quarter. Silverarc Capital Management LLC now owns 3,567,985 shares of the company’s stock valued at $8,492,000 after acquiring an additional 622,037 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Poseida Therapeutics during the fourth quarter valued at approximately $76,000. Mirae Asset Global Investments Co. Ltd. raised its position in Poseida Therapeutics by 10.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 259,929 shares of the company’s stock valued at $619,000 after acquiring an additional 23,960 shares in the last quarter. Strs Ohio bought a new position in Poseida Therapeutics during the third quarter valued at approximately $47,000. Finally, Barclays PLC raised its position in Poseida Therapeutics by 40.7% during the third quarter. Barclays PLC now owns 45,542 shares of the company’s stock valued at $109,000 after acquiring an additional 13,174 shares in the last quarter. 46.87% of the stock is owned by hedge funds and other institutional investors.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.